Polymer 3D printing and additive manufacturing solutions provider Stratasys Ltd. (NASDAQ: SSYS) announced on Monday that it is collaborating with healthcare technology company Siemens Healthineers in a pioneering research project to advance medical imaging phantoms for computed tomography (CT) imaging.
CT phantoms, crucial in medical imaging, simulate human body characteristics to evaluate CT scanner performance. The joint project uses Stratasys' PolyJet technology and RadioMatrix technology, along with Siemens Healthineers' advanced algorithm, aiming to create tailored phantoms with ultra-realistic human anatomy characteristics.
This collaboration may revolutionise medical phantom utilisation, potentially replacing human cadavers with 3D printed structures, providing efficiencies and minimising human variability.
The research will produce valuable data for advancing CT system algorithms, materials development and unlocking new application areas. The phased project starts with 3D printed phantoms for head and neck anatomies, leading to a Phase One endpoint of 3D printing a heart model and an entire human torso with complete radiographic accuracy.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration